Major corporate announcements and significant share buybacks are drawing investor attention in the Hong Kong market today.

SENASIC (ASX: 06675) has initiated its initial public offering process, which will run from June 9th to June 12th. The company plans to offer 53.407 million H shares globally.

Wuxi AppTec Co., Ltd. (ASX: 02359) has issued a statement, asserting that the basis for the company's inclusion on a specific list is completely inconsistent with the facts.

Consun Pharmaceutical Group Limited (ASX: 01681) intends to acquire a 30% equity stake in Shanghai Huamao Pharmaceutical Co., Ltd.

A change in controlling interest is expected at Contel-NEW (ASX: 01912), with a mandatory general offer being made at a discount of approximately 34.82%. Trading in the company's shares is set to resume on June 9th.

Estun Automation Co., Ltd. (ASX: 02715) has reported abnormal trading volatility in its A-shares, clarifying that there are no undisclosed material events that should be announced.

Remegen Co., Ltd. (ASX: 09995) announced that its drug, Telitacicept for injection, has received approval for a new indication in the treatment of Sjögren's syndrome.

Furthermore, Remegen Co., Ltd. (ASX: 09995) stated that the National Medical Products Administration has conditionally approved the marketing application for Telitacicept injection (RC18) for a new indication treating IgA nephropathy.

Fusen Pharmaceutical Co., Ltd. (ASX: 01652) has received approval for the market launch of its "Agomelatine Tablets."

CSPC Pharmaceutical Group Limited (ASX: 01093) announced that its long-acting injection of Semaglutide (SYH 9017) has received approval for clinical trials in the United States.

Significant Share Repurchases and Ownership Changes

On June 8th, AIA Group Limited (ASX: 01299) spent approximately HK$680 million to repurchase 9.352 million shares.

Tencent Holdings Limited (ASX: 00700) invested HK$501 million to buy back 1.116 million shares on the same day.

Wuxi Biologics (Cayman) Inc. (ASX: 02269) allocated HK$200 million for the repurchase of 653,700 shares.

Li Auto Inc. (ASX: 02015) utilized HK$150 million to repurchase 262,670 shares.

Kuaishou Technology (ASX: 01024) spent HK$89.9519 million to repurchase 204,200 shares.

Midea Group Co., Ltd. (ASX: 00300) used RMB 79.8004 million to repurchase 965,000 A-shares.

Zhuzhou CRRC Times Electric Co., Ltd. (ASX: 03898) invested HK$72.4868 million to repurchase 1.8371 million shares.

Eastroc Beverage (Group) Co., Ltd. (ASX: 09980) allocated RMB 49.9984 million to repurchase 367,900 A-shares.

Ribo Life Science Co., Ltd. (ASX: 06938) plans to use up to RMB 200 million for an H-share incentive plan and to implement a share buyback, demonstrating confidence in its development.

SF Intra-City Industrial Co., Ltd. (ASX: 09699) intends to repurchase up to HK$400 million worth of H-shares.

Zhaoke Ophthalmology Limited (ASX: 06622) plans to repurchase up to HK$100 million in shares.

China Hongqiao Group Limited (ASX: 01378) saw its controlling shareholder, China Hongqiao Holdings, increase its stake by 21 million shares.

Chinasoft International Limited (ASX: 00354) had its major shareholder, Chairman, and Executive Director, Chen Yuhong, increase his holding by 3 million shares.

Ruichang International Holdings Limited (ASX: 01334) had its controlling shareholder, Lu Bo, increase his stake by 1.37 million shares.

Breton Limited (ASX: 01333) saw its director and controlling shareholder, Chen Fangming, increase his holding by 103,000 shares.